Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

CLSD

Clearside Biomedical Inc

Last Close
May 17 • 04:00PM ET
1.31
Dollar change
0.00
Percentage change
0.00 		%
Held by: VTI VXF IWC
Index- P/E- EPS (ttm)-0.54 Insider Own15.79% Shs Outstand74.73M Perf Week4.80%
Market Cap97.90M Forward P/E- EPS next Y-0.57 Insider Trans4.90% Shs Float62.93M Perf Month-0.76%
Income-34.97M PEG- EPS next Q-0.13 Inst Own23.74% Short Float0.54% Perf Quarter4.80%
Sales8.45M P/S11.59 EPS this Y-4.71% Inst Trans-7.09% Short Ratio0.89 Perf Half Y36.46%
Book/sh-0.29 P/B- EPS next Y-3.60% ROA-82.44% Short Interest0.34M Perf Year25.96%
Cash/sh0.47 P/C2.77 EPS next 5Y- ROE-1310.02% 52W Range0.65 - 2.12 Perf YTD11.97%
Dividend Est.- P/FCF- EPS past 5Y27.88% ROI-151.03% 52W High-38.21% Beta2.34
Dividend TTM- Quick Ratio6.07 Sales past 5Y1621.13% Gross Margin94.85% 52W Low101.51% ATR (14)0.10
Dividend Ex-Date- Current Ratio6.07 EPS Y/Y TTM5.00% Oper. Margin-301.09% RSI (14)49.26 Volatility4.81% 7.69%
Employees30 Debt/Eq- Sales Y/Y TTM758.94% Profit Margin-413.72% Recom1.00 Target Price5.20
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-11.01% Payout- Rel Volume0.55 Prev Close1.31
Sales Surprise-60.68% EPS Surprise-23.19% Sales Q/Q5650.00% EarningsMay 09 AMC Avg Volume378.69K Price1.31
SMA200.58% SMA50-8.39% SMA20013.40% Trades Volume209,159 Change0.00%
Date Action Analyst Rating Change Price Target Change
Dec-15-21Resumed Wedbush Outperform $19 → $9
Jul-29-21Initiated H.C. Wainwright Buy $10
May-13-20Initiated ROTH Capital Buy $8
Aug-09-19Downgrade Needham Buy → Hold
Nov-05-18Downgrade Stifel Buy → Hold
Nov-05-18Downgrade JP Morgan Overweight → Underweight
Nov-05-18Downgrade Cowen Outperform → Market Perform
Mar-06-18Reiterated Needham Buy $18 → $22
May-25-17Initiated JMP Securities Mkt Outperform $21
Feb-24-17Initiated JP Morgan Overweight $19
Show Previous Ratings
May-13-24 08:20AM
HC Wainwright Adjusts Price Target on Clearside Biomedical to $5 From $6, Keeps Buy Rating
(MT Newswires)
May-10-24 02:15PM
Q1 2024 Clearside Biomedical Inc Earnings Call
(Thomson Reuters StreetEvents) -7.41%
11:56AM
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q1 2024 Earnings Call Transcript
(Insider Monkey)
May-09-24 06:55PM
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
(Zacks) +6.30%
04:05PM
Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update
(GlobeNewswire)
04:15PM Loading…
May-08-24 04:15PM
Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference
(GlobeNewswire)
Apr-30-24 07:05AM
Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024
(GlobeNewswire)
Apr-16-24 07:05AM
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
(GlobeNewswire) -10.85%
Apr-02-24 07:05AM
Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
(GlobeNewswire) -11.39%
Mar-18-24 07:05AM
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
(GlobeNewswire) -8.77%
Mar-13-24 08:30AM
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call Transcript
(Insider Monkey)
06:38AM
Q4 2023 Clearside Biomedical Inc Earnings Call
(Thomson Reuters StreetEvents)
Mar-12-24 05:35PM
Clearside Biomedical Inc (CLSD) Reports Significant Licensing Revenue Growth in Q4 and Full ...
(GuruFocus.com) -18.81%
04:05PM
Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
(GlobeNewswire)
Mar-06-24 02:25PM
These 2 Strong Buy Penny Stocks Could Surge Over 200%, Say Analysts
(TipRanks) +8.63%
07:05AM Loading…
Feb-29-24 07:05AM
Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024
(GlobeNewswire)
Feb-25-24 01:37PM
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
(InvestorPlace)
Feb-07-24 08:00AM
Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering
(GlobeNewswire)
Dec-14-23 07:05AM
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
(GlobeNewswire)
Nov-14-23 09:11AM
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2023 Earnings Call Transcript
(Insider Monkey)
Nov-13-23 04:05PM
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
(GlobeNewswire)
Nov-08-23 07:05AM
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference
(GlobeNewswire) -9.65%
Nov-07-23 04:20PM
Clearside Biomedical's Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting
(GlobeNewswire)
Nov-03-23 12:00PM
BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside's Proprietary SCS Microinjector
(GlobeNewswire) +19.39%
Nov-02-23 07:05AM
Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting
(GlobeNewswire)
Nov-01-23 07:05AM
Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD
(GlobeNewswire) +5.30%
Oct-31-23 07:05AM
Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023
(GlobeNewswire) +5.17%
Oct-26-23 12:24AM
3 Cheap Stocks to Buy Under $1 in October 2023
(InvestorPlace) -5.28%
Oct-16-23 07:05AM
Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting
(GlobeNewswire)
Oct-04-23 09:00AM
Clearside Biomedical Announces Advancement of XIPERE in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China
(GlobeNewswire)
04:35PM Loading…
Oct-03-23 04:35PM
Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit
(GlobeNewswire)
Sep-19-23 07:05AM
Clearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare Conference
(GlobeNewswire)
Aug-14-23 04:05PM
Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update
(GlobeNewswire)
Aug-02-23 04:30PM
Clearside Biomedical to Participate in Upcoming Investor Conferences in August 2023
(GlobeNewswire)
Aug-01-23 07:05AM
Clearside Biomedical to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Monday, August 14, 2023
(GlobeNewswire)
Jul-31-23 07:05AM
Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation at the American Society of Retina Specialists 41st Annual Scientific Meeting
(GlobeNewswire)
Jul-20-23 07:05AM
Clearside Biomedicals Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings
(GlobeNewswire)
Jul-11-23 04:05PM
Clearside Biomedical CEO George Lasezkay to Present at the SHARE Series Investor Event on Monday, July 17, 2023
(GlobeNewswire)
Jul-10-23 07:05AM
Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema
(GlobeNewswire)
Jun-29-23 09:50AM
We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate
(Simply Wall St.)
Jun-01-23 07:05AM
Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD
(GlobeNewswire)
May-11-23 08:25AM
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
(Zacks) -6.90%
07:05AM
Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update
(GlobeNewswire)
May-09-23 04:30PM
Clearside Biomedical to Participate in a Fireside Chat at the JMP Securities Life Sciences Conference
(GlobeNewswire)
May-02-23 07:05AM
Clearside Biomedical to Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023
(GlobeNewswire)
Apr-27-23 07:05AM
Clearside Biomedical Presents Compelling Data at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
(GlobeNewswire)
Apr-18-23 07:05AM
Clearside Biomedical Announces Plans for ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD
(GlobeNewswire)
Apr-12-23 07:05AM
Clearside Biomedical to Participate in a Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference
(GlobeNewswire) -10.48%
Apr-09-23 09:42AM
Clearside Biomedical (NASDAQ:CLSD) adds US$12m to market cap in the past 7 days, though investors from five years ago are still down 88%
(Simply Wall St.)
Apr-05-23 07:05AM
Clearside Biomedical Enhances Scientific Advisory Board with the Appointment of Two Distinguished Retinal Physicians
(GlobeNewswire) -8.89%
Mar-11-23 03:14AM
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2022 Earnings Call Transcript
(Insider Monkey)
Mar-09-23 06:35PM
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates
(Zacks)
04:05PM
Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
(GlobeNewswire)
Feb-23-23 07:05AM
Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023
(GlobeNewswire) -5.26%
Feb-21-23 07:05AM
Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings
(GlobeNewswire)
Feb-07-23 07:05AM
Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023
(GlobeNewswire)
Feb-06-23 07:30AM
Clearside Biomedical Announces Leadership Team Update
(GlobeNewswire)
Feb-02-23 01:18PM
Clearside Biomedical Touts Encouraging Durable Data From Investigational Candidate For Vision Disorder
(Benzinga)
07:05AM
Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD
(GlobeNewswire)
Dec-22-22 09:52AM
2 Strong Buy Penny Stocks That Could Go Boom
(TipRanks) +8.00%
05:05AM
Companies Like Clearside Biomedical (NASDAQ:CLSD) Can Afford To Invest In Growth
(Simply Wall St.)
Nov-22-22 07:05AM
Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022
(GlobeNewswire)
Nov-11-22 05:26AM
Clearside Biomedical Third Quarter 2022 Earnings: Beats Expectations
(Simply Wall St.)
Nov-10-22 01:24PM
Analyst Bumps Up Clearside Biomedical Target Price After Encouraging Trial Data
(Benzinga)
07:05AM
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference
(GlobeNewswire)
Nov-09-22 09:05AM
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates
(Zacks) -8.57%
07:15AM
Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update
(GlobeNewswire)
07:05AM
Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients
(GlobeNewswire)
Nov-08-22 04:05PM
Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results
(GlobeNewswire)
Nov-02-22 07:05AM
Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022
(GlobeNewswire) +11.57%
Oct-31-22 08:52AM
Investors in Clearside Biomedical (NASDAQ:CLSD) have unfortunately lost 84% over the last five years
(Simply Wall St.)
Oct-17-22 11:27AM
Wave Life Sciences (WVE) Soars 13.8%: Is Further Upside Left in the Stock?
(Zacks)
Oct-04-22 07:05AM
Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedicals Proprietary Suprachoroidal Space Platform
(GlobeNewswire) +14.17%
Sep-27-22 07:05AM
Clearside Biomedical to Present Corporate Overview and Upcoming Catalysts at Eyecelerator at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
(GlobeNewswire)
Aug-25-22 07:05AM
Clearside Biomedical to Present at the Ophthalmology Futures Retina Forum 2022
(GlobeNewswire)
Aug-11-22 06:21AM
These Analysts Think Clearside Biomedical, Inc.'s (NASDAQ:CLSD) Sales Are Under Threat
(Simply Wall St.)
Aug-09-22 08:35AM
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates
(Zacks)
07:05AM
Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update
(GlobeNewswire)
Aug-08-22 04:30PM
Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million
(GlobeNewswire)
08:05AM
ANI Pharmaceuticals (ANIP) Tops Q2 Earnings and Revenue Estimates
(Zacks)
Aug-03-22 07:05AM
Clearside Biomedical to Participate in Three Upcoming Investor Conferences in August 2022
(GlobeNewswire)
Jul-27-22 07:05AM
Clearside Biomedical to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Tuesday, August 9, 2022
(GlobeNewswire)
Jul-26-22 07:05AM
Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients
(GlobeNewswire)
Jul-09-22 08:25AM
Here's What Clearside Biomedical, Inc.'s (NASDAQ:CLSD) Shareholder Ownership Structure Looks Like
(Simply Wall St.)
Jul-07-22 07:05AM
Clearside Biomedical Suprachoroidal Delivery Technology to be Featured at Upcoming ASRS and OIS Medical Meetings
(GlobeNewswire) +7.80%
Jun-14-22 07:05AM
Clearside Biomedical Expands Leadership Team with Appointment of Susan Coultas, Ph.D., as Chief Clinical Officer
(GlobeNewswire)
Jun-08-22 07:05AM
Clearside Biomedical to Participate in the JMP Securities Life Sciences Conference
(GlobeNewswire)
May-11-22 05:25PM
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
(Zacks) -7.64%
04:05PM
Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update
(GlobeNewswire)
May-05-22 07:05AM
Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technology
(GlobeNewswire) -6.13%
Apr-29-22 07:05AM
Clearside Biomedical to Report First Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, May 11, 2022
(GlobeNewswire) -5.56%
Apr-11-22 07:44AM
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Stock Jumps 24.5%: Will It Continue to Soar?
(Zacks)
Apr-06-22 07:05AM
Clearside Biomedical to Present at the Needham Virtual Healthcare Conference
(GlobeNewswire)
Mar-28-22 06:59AM
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
(PR Newswire)
Mar-15-22 06:38PM
Clearside Stock Is up Over 80% In Three Trading Days. How Much Higher Can It Go?
(TipRanks) +19.71%
Mar-10-22 05:25PM
Clearside Biomedical, Inc. (CLSD) Q4 Earnings and Revenues Beat Estimates
(Zacks) -9.40%
04:05PM
Clearside Biomedical Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
(GlobeNewswire)
Mar-03-22 07:05AM
Clearside Biomedical Appoints Benjamin R. Yerxa, Ph.D. to its Board of Directors
(GlobeNewswire)
Mar-01-22 07:05AM
Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2022
(GlobeNewswire) -6.58%
Feb-28-22 08:25AM
Arvinas, Inc. (ARVN) Reports Q4 Loss, Tops Revenue Estimates
(Zacks)
Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
YERXA BENJAMIN RDirectorMay 15 '24Buy1.317,81310,23517,957May 15 05:28 PM
Gibney Anthony SDirectorApr 18 '24Buy1.3093,290121,277100,000Apr 19 09:45 AM
Gibney Anthony SDirectorApr 17 '24Buy1.256,7108,3886,710Apr 19 09:45 AM
Chong Ngai Hang VictorCHIEF MEDICAL OFFICERMar 20 '24Buy1.6030,00048,00030,000Mar 20 04:30 PM
WHITMORE BRADFORD T10% OwnerFeb 07 '24Buy1.35444,444599,9994,495,034Feb 09 01:00 PM
LASEZKAY GEORGE MCEOJan 19 '24Sale1.2718,00022,860466,577Jan 19 06:26 PM
Deignan Charles A.Chief Financial OfficerJan 19 '24Sale1.2812,90016,512384,662Jan 19 06:25 PM
WHITMORE BRADFORD T10% OwnerNov 01 '23Buy0.7464,36647,9014,050,590Nov 01 04:24 PM
WHITMORE BRADFORD T10% OwnerOct 31 '23Buy0.7370,81251,5373,986,224Nov 01 04:24 PM
WHITMORE BRADFORD T10% OwnerOct 30 '23Buy0.696004113,915,412Nov 01 04:24 PM
Hutson Nancy JDirectorOct 03 '23Buy0.8610,0008,60093,000Oct 04 05:06 PM
Thorp ClayDirectorSep 25 '23Buy0.8610,0008,60040,522Sep 25 04:34 PM
Humphries William D.DirectorSep 22 '23Option Exercise0.4022,7279,09151,040Sep 22 04:35 PM
Deignan Charles A.Chief Financial OfficerSep 13 '23Option Exercise0.4034,09013,636397,562Sep 13 06:55 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

VIGL

Vigil Neuroscience Inc

Last Close
May 17 • 04:00PM ET
3.52
Dollar change
-0.02
Percentage change
-0.56 		%
Held by: VTI IWM IWN VXF VTWO IWC VTWV GSSC URTY UWM
IndexRUT P/E- EPS (ttm)-2.12 Insider Own47.96% Shs Outstand35.88M Perf Week10.69%
Market Cap132.28M Forward P/E- EPS next Y-1.92 Insider Trans0.02% Shs Float19.56M Perf Month28.00%
Income-82.78M PEG- EPS next Q-0.55 Inst Own39.10% Short Float5.95% Perf Quarter16.17%
Sales0.00M P/S- EPS this Y9.96% Inst Trans28.17% Short Ratio11.89 Perf Half Y-47.15%
Book/sh2.76 P/B1.27 EPS next Y-0.38% ROA-52.16% Short Interest1.16M Perf Year-58.56%
Cash/sh2.70 P/C1.30 EPS next 5Y- ROE-60.18% 52W Range2.50 - 11.11 Perf YTD4.14%
Dividend Est.- P/FCF- EPS past 5Y- ROI-71.07% 52W High-68.32% Beta2.03
Dividend TTM- Quick Ratio12.38 Sales past 5Y0.00% Gross Margin- 52W Low40.80% ATR (14)0.32
Dividend Ex-Date- Current Ratio12.38 EPS Y/Y TTM0.09% Oper. Margin0.00% RSI (14)57.35 Volatility10.02% 11.44%
Employees69 Debt/Eq0.13 Sales Y/Y TTM- Profit Margin- Recom1.50 Target Price16.75
Option/ShortNo / Yes LT Debt/Eq0.12 EPS Q/Q2.59% Payout- Rel Volume0.50 Prev Close3.54
Sales Surprise- EPS Surprise17.45% Sales Q/Q- EarningsMay 07 AMC Avg Volume97.85K Price3.52
SMA2016.06% SMA5013.67% SMA200-19.42% Trades Volume49,236 Change-0.56%
Date Action Analyst Rating Change Price Target Change
Dec-19-23Downgrade Morgan Stanley Equal-Weight → Underweight $13 → $4
Oct-18-23Initiated JMP Securities Mkt Outperform $23
Mar-31-23Initiated Mizuho Buy $15
Sep-16-22Initiated Wedbush Outperform $19
Aug-29-22Initiated H.C. Wainwright Buy $24
Feb-01-22Initiated Stifel Buy $24
Feb-01-22Initiated Morgan Stanley Equal-Weight $17
Feb-01-22Initiated Jefferies Buy $20
Feb-01-22Initiated Guggenheim Buy $23
May-08-24 07:40AM
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
(GlobeNewswire) +18.50%
May-07-24 10:55PM
VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q1 2024
(InvestorPlace) +10.38%
09:08PM
Vigil Neuroscience Inc (VIGL) Q1 2024 Earnings: Challenges Persist Amid Clinical Developments
(GuruFocus.com)
04:05PM
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
(GlobeNewswire)
Apr-17-24 04:05PM
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
(GlobeNewswire)
01:53PM Loading…
Mar-26-24 01:53PM
VIGL Stock Earnings: Vigil Neuroscience Misses EPS for Q4 2023
(InvestorPlace) -7.00%
07:05AM
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
(GlobeNewswire)
Mar-20-24 07:05AM
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
(GlobeNewswire) +9.18%
Mar-13-24 07:05AM
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
(GlobeNewswire)
Mar-12-24 07:05AM
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
(GlobeNewswire) -5.99%
Mar-06-24 04:25PM
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
(GlobeNewswire)
Feb-29-24 04:05PM
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024
(GlobeNewswire)
Feb-07-24 04:05PM
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference
(GlobeNewswire)
Jan-03-24 04:30PM
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones
(GlobeNewswire)
Nov-22-23 04:05PM
Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference
(GlobeNewswire) -9.17%
04:05PM Loading…
Nov-16-23 04:05PM
Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
(GlobeNewswire)
Nov-07-23 07:05AM
Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update
(GlobeNewswire) -9.34%
Oct-18-23 09:52AM
Arm initiated, SQM downgraded: Wall Street's top analyst calls
(The Fly)
Oct-17-23 07:05AM
Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer's Disease
(GlobeNewswire) +6.65%
Oct-05-23 04:01PM
Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
(GlobeNewswire)
Sep-26-23 07:05AM
Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP
(GlobeNewswire)
Sep-11-23 12:00PM
Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting
(GlobeNewswire)
Sep-08-23 04:05PM
Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program
(GlobeNewswire)
07:05AM
Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference
(GlobeNewswire)
Aug-08-23 07:05AM
Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update
(GlobeNewswire)
Aug-07-23 04:05PM
Vigil Neuroscience Appoints Christopher J. Silber, M.D. as Chief Medical Officer
(GlobeNewswire) -8.33%
Jun-01-23 07:00AM
Vigil Neuroscience to Present at 2023 Jefferies Global Healthcare Conference
(GlobeNewswire)
May-10-23 07:00AM
Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update
(GlobeNewswire)
May-09-23 07:00AM
Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors
(GlobeNewswire)
May-08-23 08:30AM
Vigil Neuroscience (NASDAQ:VIGL) Is In A Good Position To Deliver On Growth Plans
(Simply Wall St.)
07:08AM Loading…
07:08AM
Vigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
(GlobeNewswire)
Mar-30-23 07:00AM
Vigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101
(GlobeNewswire)
Mar-22-23 07:00AM
Vigil Neuroscience to Present at Stifel 2023 CNS Days
(GlobeNewswire) +10.82%
Mar-21-23 07:00AM
Vigil Neuroscience Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
(GlobeNewswire)
Mar-02-23 04:00PM
Vigil Neuroscience Announces Multiple Presentations on Lead Indication ALSP at the 2023 American Academy of Neurology Annual Meeting
(GlobeNewswire)
Jan-03-23 07:00AM
Vigil Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare Conference
(GlobeNewswire)
Dec-15-22 04:01PM
Vigil Neuroscience Appoints David Gray, Ph.D., as Chief Scientific Officer and Announces Changes to Executive Team
(GlobeNewswire)
Dec-14-22 04:01PM
Vigil Neuroscience Announces First Patient Dosed in the IGNITE Phase 2 Clinical Trial to Evaluate VGL101 in Patients with ALSP
(GlobeNewswire) +6.66%
Nov-29-22 05:23AM
We Think Vigil Neuroscience (NASDAQ:VIGL) Can Afford To Drive Business Growth
(Simply Wall St.)
Nov-28-22 07:00AM
Vigil Neuroscience to Host ALSP KOL Event on December 6, 2022
(GlobeNewswire) +11.46%
Nov-10-22 07:00AM
Vigil Neuroscience Reports Third Quarter 2022 Financial Results and Provides Business Update
(GlobeNewswire) -23.86%
Nov-07-22 07:00AM
Vigil Neuroscience to Present at Upcoming Investor Conferences
(GlobeNewswire) +10.07%
Nov-02-22 12:43PM
Vigil Neuroscience Touts Positive Healthy Volunteer Data From Lead Program In Rare Neurological Disease
(Benzinga) -12.04%
07:00AM
Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP
(GlobeNewswire)
Nov-01-22 07:00AM
Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP
(GlobeNewswire)
Oct-12-22 07:58AM
7 Short-Squeeze Stocks to Buy for Contrarian Investors
(InvestorPlace) +37.01%
Sep-14-22 09:55AM
Wall Street Analysts Predict a 121% Upside in Vigil Neuroscience, Inc. (VIGL): Here's What You Should Know
(Zacks)
Sep-01-22 07:00AM
Vigil Neuroscience to Present at 2022 Morgan Stanley Global Healthcare Conference
(GlobeNewswire)
Aug-29-22 09:55AM
How Much Upside is Left in Vigil Neuroscience, Inc. (VIGL)? Wall Street Analysts Think 133%
(Zacks)
Aug-12-22 09:55AM
Wall Street Analysts Believe Vigil Neuroscience, Inc. (VIGL) Could Rally 167%: Here's is How to Trade
(Zacks) +8.34%
07:00AM
Vigil Neuroscience Announces $75 Million Private Placement Financing
(GlobeNewswire)
Aug-08-22 07:00AM
Vigil Neuroscience Reports Second Quarter 2022 Financial Results and Provides Business Update
(GlobeNewswire)
Aug-02-22 07:00AM
Vigil Neuroscience to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference
(GlobeNewswire)
Aug-01-22 07:00AM
Vigil Neuroscience Presents Preclinical Data on VGL101 for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) and Clinical Phenotype of ALSP at Alzheimer's Association International Conference 2022
(GlobeNewswire)
Jul-28-22 07:00AM
Vigil Neuroscience Strengthens Board of Directors with Appointment of Suzanne Bruhn, Ph.D.
(GlobeNewswire)
Jun-09-22 09:58AM
7 No-Brainer Biotech Stocks to Add to Your Buy List
(InvestorPlace)
Jun-07-22 07:00AM
Vigil Neuroscience Expands VGL101 Phase 1 Trial to Australia
(GlobeNewswire) +10.20%
Jun-01-22 07:00AM
Vigil Neuroscience to Present at 2022 Jefferies Global Healthcare Conference
(GlobeNewswire)
May-12-22 07:00AM
Vigil Neuroscience Reports First Quarter 2022 Financial Results and Provides Business Highlights
(GlobeNewswire)
Apr-20-22 07:00AM
Vigil Neuroscience Expands Leadership Team and Board of Directors
(GlobeNewswire)
Apr-08-22 12:33PM
We Think Vigil Neuroscience (NASDAQ:VIGL) Needs To Drive Business Growth Carefully
(Simply Wall St.)
Mar-25-22 06:30AM
Vigil Neuroscience Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights
(GlobeNewswire) -6.94%
Mar-21-22 07:00AM
Vigil Neuroscience to Present at Stifel 2022 CNS Days
(GlobeNewswire) -24.37%
Mar-03-22 04:05PM
Vigil Neuroscience to Present Key Considerations for Lead Indication ALSP at the 2022 American Academy of Neurology Annual Meeting
(GlobeNewswire)
Jan-27-22 01:46PM
Wall Street gyrations may thwart deal closings, IPO outlook
(American City Business Journals)
05:30AM
New Year, Fresh Stocks: 3 IPOs That Joined the Market in January
(Motley Fool)
Jan-11-22 04:01PM
Vigil Neuroscience Announces Closing of Initial Public Offering
(GlobeNewswire)
Jan-06-22 11:07PM
Vigil Neuroscience Announces Pricing of Initial Public Offering
(GlobeNewswire)
Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. Its focus is improving the lives of patients, caregivers, and families affected by neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. The company was founded on June 22, 2020 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Magovcevic-Liebisch IvanaPresident and CEONov 20 '23Buy3.754,00015,000207,687Nov 20 06:34 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.